🚨 New in NEJM — The ALASCCA Trial 🧬

Low-dose aspirin (160 mg/day) reduced colorectal cancer recurrence in patients with PIK3CA, PIK3R1, or PTEN mutations 🎯

✅ 3-year recurrence: 7.7% (aspirin) vs 14–17% (placebo)

✅ Group A HR: 0.49 | Group B HR: 0.42

✅ NNT as low as 6 in stage III rectal cancer 💥

⚠️ Slight increase in adverse events

🧠 Editorial calls it a new standard of care:

🔬 Genotype early + 💊 Start aspirin early = 📉 Lower recurrence

📖 Read both the trial and editorial in NEJM, Sept 2025

#ColorectalCancer #PrecisionOncology #Aspirin #PIK3CA #NEJM #OncologyTrials #Genomics #AdjuvantTherapy #ALASCCA #ClinicalTrials